OncoSec Medical Incorporated (NASDAQ:ONCS) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 1,185,865 shares, a decrease of 36.0% from the June 15th total of 1,851,875 shares. Based on an average trading volume of 170,038 shares, the days-to-cover ratio is currently 7.0 days. Currently, 5.8% of the company’s shares are short sold.

A number of analysts have recently commented on the company. Dawson James reaffirmed a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Thursday, July 6th. ValuEngine raised OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, July 14th. Maxim Group set a $5.00 price target on OncoSec Medical and gave the company a “buy” rating in a research note on Saturday, June 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of OncoSec Medical in a research note on Friday, June 2nd. Finally, Noble Financial reaffirmed a “buy” rating on shares of OncoSec Medical in a research note on Friday, May 12th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $5.33.

OncoSec Medical (ONCS) traded up 0.0104% during mid-day trading on Monday, reaching $0.9601. The company had a trading volume of 13,984 shares. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The firm’s 50-day moving average is $1.08 and its 200-day moving average is $1.17. The firm’s market capitalization is $20.32 million.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.06. On average, equities research analysts anticipate that OncoSec Medical will post ($1.02) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/14/oncosec-medical-incorporated-nasdaqoncs-short-interest-update-updated-updated-updated.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.